1. Scrip
  2. >>Therapy Areas

Apellis Aims New Pegcetacoplan Data At Market, Not Regulators

 
• By Alaric DeArment

The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.

Apellis said it was submitting new, longer-term follow-up data to the FDA for its geographic atrophy drug • Source: Shutterstock

Apellis Pharmaceuticals, Inc. is looking at a three-month extension of the US Food and Drug Administration action date for its pegcetacoplan in geographic atrophy (GA), but that’s because it is choosing to submit additional data to the agency. The firm opted for the short delay in order to have a more compelling dataset to take to the market.

Apellis said 3 November that it would submit 24-month Phase III data from the 637-patient DERBY and 621-patient OAKS clinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.